|
|
 |
|
Viewing report
|
|
|
|
Market Access Brazil: Unlocking Pharma Potential.
FirstWord Publishing, July 2011, Pages: 38
With this year’s election of president Dilma Rousseff, Brazil has indicated a willingness to encourage long-term foreign investment in the pharmaceutical industry. Yet while Rousseff has set three critical path priorities to ensure investment flows into the country, there are serious concerns. Price setting, the ‘big stick’ of the compulsory licenses, burdensome tax laws, slow product approvals and linguistic barriers have all emerged as key issues. Complicating matters is competition from government-favoured generics and a high volume in illegally-traded drugs, which represent 25 percent of all pharmaceuticals sold.
Yet while those issues may seem insurmountable, gaining access to the fast-growing and potentially rich Brazilian market is not impossible—with the right information.
Report Overview
Market Access Brazil: Unlocking Pharma Potential lays bare the otherwise complex operations of the Brazilian health industry. From an examination of health care responsibilities and the role of the National Health Surveillance Agency (ANVISA) to consumer trends, the latest patent protection issues, the role of generics and ongoing battle over intellectual property, the report provides clear insight into an evolving landscape. Containing interviews with experts, financial comparatives and updates from multinationals in the region, the report offers a compelling overview of Brazil’s pharmaceutical industry.
Key features
- Breakdown of market trends and where opportunities exist
- Examination of intellectual property and price controls and their impact on foreign pharmaceutical manufacturers
- Role of generics, their phenomenal success and its impact on market share for the top ten producers
- Explanation of licensing agreements, their loopholes and legislation to close them
- Outline of investing within a protectionist environment, with a look at agreements that impact the pharma industry
- Company updates on Pfizer, sanofi-aventis, Laboratorios Silanes de Mexico, Amgen, Hypermarcas de Brazil and GlaxoSmithKline amongst others
Key Benefits
- Clear insight into the complex and evolving regulatory landscape in Brazil
- A roadmap to the barriers and potholes facing multinationals
- Expert analysis of key issues facing the industry
Key Questions Asked
- How is the political situation in Brazil impacting overseas investment by pharma?
- What barriers exist to market access and how can they be overcome?
- What are the emerging trends in intellectual property, licensing agreements and patent protection?
- What response has been made to questions about price control?
Who Should Read This Report
- Market Access directors and managers
- Pricing and reimbursement professionals
- Health economics professionals
- Medical affairs professionals
- Regulatory affairs teams and advisors
- Heads of marketing and sales
- Brand directors and managers
- Therapy area heads
- Emerging market leads
- Country managers
Expert Views
- Marin Osorio, Senior Secretary, Brazilian Ministry of Health
- Odinir Finotti, President, Pró Genéricos
- Patrice Grand, Latin American affairs, Bristol-Myers Squibb
- Ricardo Mendes da Silva, President, Aché Laboratórios Farmacêuticos
- Maximilian Gorissen, Compustream Consultoria Ltda
- Ricardo Ruiz, Adjunct Professor, Federal University of Minas Gerais
- Emilio Wien, Health Economist, Brazilian Ministry of Health
Key Quotes:
“That’s what we would say to foreign companies looking at the market: even if you’re going to stick with brand-name products, make them of the low-cost/high-quality variety if you want them to compete and reach high sales volumes.”
– Dr Flavio Vormittag, managing director, US Pharmacopeia.
“The advantage of this [Industrial Property Law], we think, is its clarity and unambiguousness: that is, it is not easily open to misinterpretation or reinterpretation. It helps to develop the national pharmaceutical industry, providing jobs, bringing technological know-how and encouraging the development of a national scientific and R&D base”
– Marin Osorio, Senior Secretary, Brazilian Ministry of Health.
“[Increasing R&D] has to happen if the Brazilian market is going to become more than just a strong producer of generics, the formulas for which have been researched and developed by others. We have to foment more of an innovative mind-set, you know, in Brazil.”
– Odinir Finotti, President, Pró Genéricos.
|
|
|
|
